Amicus Therapeutics announced today that the Company has suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 (1-deoxynojirimycin HCI) for the treatment of Pompe Disease and that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold. After evaluation of available data the Company plans to work closely with the FDA and if appropriate will amend the Phase 2 protocol with the objective of restarting the trial as expeditiously as possible.
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe
Feb 27, 2009 | NEWS
News Archives
- August 2024 (2)
- June 2024 (1)
- May 2024 (1)
- February 2024 (1)
- January 2024 (1)
- December 2023 (2)
- October 2023 (1)
- August 2023 (3)
- July 2023 (1)
- February 2023 (1)
- January 2023 (1)
- November 2022 (1)
- September 2022 (2)
- June 2022 (1)
- May 2022 (2)
- February 2022 (4)
- January 2022 (3)
- November 2021 (1)
- October 2021 (2)
- September 2021 (1)
- August 2021 (13)
- July 2021 (2)
- June 2021 (1)
- April 2021 (1)
- February 2021 (1)
- January 2021 (1)
- July 2020 (4)
- March 2020 (4)
- January 2020 (1)
- December 2019 (1)
- November 2019 (1)
- August 2019 (2)
- January 2019 (1)
- December 2018 (1)
- October 2018 (2)
- September 2018 (3)
- June 2018 (1)
- August 2017 (1)
- July 2017 (1)
- May 2017 (2)
- February 2017 (1)
- January 2017 (2)
- November 2016 (1)
- September 2016 (1)
- July 2016 (1)
- June 2016 (2)
- April 2016 (4)
- March 2016 (1)
- February 2016 (1)
- January 2016 (2)
- December 2015 (2)
- August 2015 (1)
- July 2015 (1)
- May 2015 (1)
- April 2015 (2)
- March 2015 (2)
- February 2015 (2)
- January 2015 (1)
- December 2014 (1)
- October 2014 (2)
- August 2014 (2)
- July 2014 (1)
- May 2014 (2)
- February 2014 (2)
- January 2014 (1)
- July 2013 (4)
- May 2013 (2)
- March 2013 (1)
- February 2013 (1)
- January 2013 (2)
- December 2012 (1)
- November 2012 (1)
- October 2012 (1)
- September 2012 (1)
- July 2012 (2)
- May 2012 (2)
- April 2012 (2)
- March 2012 (2)
- February 2012 (1)
- January 2012 (2)
- August 2011 (3)
- July 2011 (1)
- June 2011 (2)
- May 2011 (1)
- March 2011 (2)
- January 2011 (4)
- December 2010 (1)
- November 2010 (1)
- August 2010 (1)
- June 2010 (1)
- May 2010 (2)
- March 2010 (1)
- February 2010 (1)
- January 2010 (2)
- December 2009 (3)
- November 2009 (3)
- October 2009 (1)
- July 2009 (2)
- May 2009 (3)
- March 2009 (2)
- February 2009 (7)
- January 2009 (10)
- November 2008 (2)
- June 2008 (1)
- April 2008 (1)
- January 2008 (1)
- December 2007 (1)
- October 2007 (1)
- June 2007 (2)
- May 2007 (1)
- April 2007 (1)
- November 2006 (2)
- October 2006 (1)
- September 2006 (2)
- June 2006 (1)
- April 2006 (2)
- January 2006 (1)
- October 2005 (1)
- July 2005 (1)
- May 2005 (2)
- April 2005 (1)
- March 2005 (1)
- December 2004 (1)
- October 2004 (1)
- November 2003 (1)
- June 2003 (1)
- May 2003 (1)
- March 2003 (2)
- December 2002 (1)
- October 2002 (1)
- July 2002 (1)
- April 2002 (2)
- March 2002 (1)
- February 2002 (2)
- October 2001 (2)
- September 2001 (1)
- August 2001 (2)
- May 2001 (1)
- March 2001 (4)
- October 2000 (3)
- July 2000 (1)
- April 2000 (1)
- March 2000 (1)
- December 1999 (1)
- August 1999 (2)
- July 1999 (1)
- June 1999 (2)
- January 1999 (2)
- October 1998 (1)
- July 1998 (1)
- June 1998 (1)
- January 1998 (1)
- November 1996 (1)
- October 1996 (1)
Post Categories
- ARCHIVES (12)
- CONFERENCES (8)
- EDITORIALS (19)
- NEWS (205)
- PATIENTS (20)
- PUBLICATIONS (1)
- RESEARCH (2)
- Uncategorized (2)
- WEBINARS (11)